Similar Articles
831 Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
832 Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort
833 Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma
834 CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma
835 Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients
836 Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era
837 Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy
838 Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2
839 Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study
840 Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA